Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/171056
Title: Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals
Authors: Goh, Yun Shan
Rouers, Angeline
Fong, Siew-Wai
Zhuo, Nicole Ziyi
Hor, Pei Xiang
Loh, Chiew Yee
Huang, Yuling
Neo, Vanessa Kexin
Kam, Isaac Kai Jie
Wang, Bei
Ngoh, Eve Zi Xian
Salleh, Siti Nazihah Mohd
Lee, Raphael Tze Chuen
Pada, Surinder
Sun, Louisa Jin
Ong, Desmond Luan Seng
Somani, Jyoti
Lee, Eng Sing
Maurer-Stroh, Sebastian
Wang, Cheng-I.
Leo, Yee Sin
Ren, Ee Chee
Lye, David C.
Young, Barnaby Edward
Ng, Lisa F. P.
Renia, Laurent
Keywords: Science::Medicine
Issue Date: 2022
Source: Goh, Y. S., Rouers, A., Fong, S., Zhuo, N. Z., Hor, P. X., Loh, C. Y., Huang, Y., Neo, V. K., Kam, I. K. J., Wang, B., Ngoh, E. Z. X., Salleh, S. N. M., Lee, R. T. C., Pada, S., Sun, L. J., Ong, D. L. S., Somani, J., Lee, E. S., Maurer-Stroh, S., ...Renia, L. (2022). Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals. Frontiers in Immunology, 13, 1031852-. https://dx.doi.org/10.3389/fimmu.2022.1031852
Project: ACCL/19-GAP064-R20H-H 
COVID19RF-001 
COVID19RF-007 
COVID19RF-0008 
COVID19RF-060 
H/20/04/g1/006 
Journal: Frontiers in Immunology 
Abstract: The emergence of new SARS-CoV-2 variants, such as the more transmissible Delta and Omicron variants, has raised concerns on efficacy of the COVID-19 vaccines. Here, we examined the waning of antibody responses against different variants following primary and booster vaccination. We found that antibody responses against variants were low following primary vaccination. The antibody response against Omicron was almost non-existent. Efficient boosting of antibody response against all variants, including Omicron, was observed following a third dose. The antibody response against the variants tested was significantly higher at one month following booster vaccination, compared with two months following primary vaccination, for all individuals, including the low antibody responders identified at two months following primary vaccination. The antibody response, for all variants tested, was significantly higher at four months post booster than at five months post primary vaccination, and the proportion of low responders remained low (6-11%). However, there was significant waning of antibody response in more than 95% of individuals at four months, compared to one month following booster. We also observed a robust memory B cell response following booster, which remained higher at four months post booster than prior to booster. However, the memory B cell responses were on the decline for 50% of individuals at four months following booster. Similarly, while the T cell response is sustained, at cohort level, at four months post booster, a substantial proportion of individuals (18.8 - 53.8%) exhibited T cell response at four months post booster that has waned to levels below their corresponding levels before booster. The findings show an efficient induction of immune response against SARS-CoV-2 variants following booster vaccination. However, the induced immunity by the third BNT162b2 vaccine dose was transient. The findings suggest that elderly individuals may require a fourth dose to provide protection against SARS-CoV-2.
URI: https://hdl.handle.net/10356/171056
ISSN: 1664-3224
DOI: 10.3389/fimmu.2022.1031852
Schools: Lee Kong Chian School of Medicine (LKCMedicine) 
School of Biological Sciences 
Organisations: National Healthcare Group Polyclincs 
National Centre for Infectious Diseases 
Tan Tock Seng Hospital 
National University of Singapore 
Infectious Diseases Labs, A*STAR 
Rights: © 2022 Goh, Rouers, Fong, Zhuo, Hor, Loh, Huang, Neo, Kam, Wang, Ngoh, Salleh, Lee, Pada, Sun, Ong, Somani, Lee, NCID Study Group, COVID-19 Study Group, Maurer-Stroh, Wang, Leo, Ren, Lye, Young, Ng and Renia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author (s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:LKCMedicine Journal Articles

Files in This Item:
File Description SizeFormat 
fimmu-13-1031852.pdf1.45 MBAdobe PDFThumbnail
View/Open

SCOPUSTM   
Citations 20

16
Updated on Jul 14, 2024

Web of ScienceTM
Citations 20

11
Updated on Oct 25, 2023

Page view(s)

121
Updated on Jul 19, 2024

Download(s)

32
Updated on Jul 19, 2024

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.